FDA approves new Sprycel indicationThe Food and Drug Administration has given Bristol-Myers Squibb approval for a new pediatric indication for Sprycel. Sanofi, Merck get Vaxelis approvalSanofi and Merck received the FDA's approval for a new vaccine that will not have a commerical supply available in the United States prior to 2020. Lupin, AbbVie partner to develop cancer drugs Lupin and AbbVie have formed a partnership to develop Lupin's MALT1 inhibitors. Slayback gets FDA nod for generic Makena The Food and Drug Administration has approved Slayback Pharma's generic Makena, which is available in a multidose vial. Lupin's generic Onfi gets FDA approval Lupin has received the Food and Drug Administration's green light for generic Onfi, which had a market value of roughly $260.2 million. Stemline Therapeutics gets FDA green light for Elzonris The Food and Drug Administration has approved the first treatment for BPDCN, a rare blood disease. Shire gets FDA’s blessing for Motegrity Shire plans to launch Motegrity for chronic idiopathic constipation in 2019. Teva introduces generic Elidel Teva's generic Elidel cream is available in three dosage strengths for atopic dermatitis. Dr. Reddy’s launches 2 generics Dr. Reddy's is launching generic Renvela and Aggrenox, which had a market value of about $101 million and $182 million, respectively. Glenmark to make foray into branded dermatology segment Glenmark enters branded dermatology segment in the U.S., which had a market value of roughly $1.9 billion. First Previous 26 27 28 29 30 Next Last
